Literature DB >> 15693030

Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.

Mark E Sherman1, Sophia S Wang, Joseph Carreon, Susan S Devesa.   

Abstract

BACKGROUND: In the United States, detection of squamous carcinoma in situ (CIS) by screening has led to reduced rates for invasive squamous carcinoma and lower mortality. Adenocarcinoma in situ (AIS) rates also have increased, but invasive cervical adenocarcinoma rates have not declined similarly. To make inferences about the effectiveness of screening, the authors assessed mortality trends for squamous and adenocarcinoma in relation to incidence of these tumors, incidence of their precursors and survival.
METHODS: Using data from the Surveillance, Epidemiology, and End Results program (SEER), the authors tabulated incidence per 10(5) woman-years for invasive carcinomas (1976-2000) and for CIS and AIS (1976-1995) by age (< 50 years, > or = 50 years) and race (whites, blacks). Cumulative relative survival rates were tabulated for 1976-1995 and mortality rates were estimated for 1986-2000.
RESULTS: Among all groups, CIS rates approximately doubled whereas rates for invasive squamous carcinoma declined. Among younger whites, mortality declined from 1.12 to 0.93, and for older whites, mortality decreased from 5.02 to 3.82. Among younger blacks, mortality for squamous carcinoma decreased from 2.69 to 1.96. Among older blacks, the mortality rates declined from 14.88 to 9.15. Although AIS rates have increased dramatically among whites (all ages) and younger blacks, adenocarcinoma incidence and mortality rates have not changed greatly. Survival for patients did not change greatly within these age-race groups.
CONCLUSIONS: The authors concluded that increases in CIS seemed disproportionately large compared with improvements in mortality rates for squamous carcinoma. Despite increased reporting of AIS, declines in mortality for cervical adenocarcinoma have not been demonstrated conclusively. However, future analyses are required to evaluate these trends more completely.

Entities:  

Mesh:

Year:  2005        PMID: 15693030     DOI: 10.1002/cncr.20877

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  47 in total

1.  CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.

Authors:  Juan Liu; Meng Wang; Xiaoli Zhang; Qingwei Wang; Mei Qi; Jing Hu; Zhiqiang Zhou; Chunyan Zhang; Weifang Zhang; Weiming Zhao; Xiao Wang
Journal:  Tumour Biol       Date:  2015-09-24

2.  Secondary malignancies of the uterine cervix: a potential diagnostic pitfall.

Authors:  Gian Franco Zannoni; Valerio Gaetano Vellone; Marco Petrillo; Guido Fadda; Esther Diana Rossi; Giovanni Scambia; Arnaldo Carbone
Journal:  Virchows Arch       Date:  2013-06-10       Impact factor: 4.064

3.  Cervical cancer trends in the United States: a 35-year population-based analysis.

Authors:  Olusola Adegoke; Shalini Kulasingam; Beth Virnig
Journal:  J Womens Health (Larchmt)       Date:  2012-07-20       Impact factor: 2.681

4.  [Silencing of SLP-2 inhibits the migration and invasion of cervical cancer cells in vitro].

Authors:  Jialu Zhang; Guolin Hu; Lei Liu; Huodi Chen; Danjuan Li; Weijiang Liang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

5.  Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.

Authors:  Jeffrey N Roberts; Rhonda C Kines; Hormuzd A Katki; Douglas R Lowy; John T Schiller
Journal:  J Natl Cancer Inst       Date:  2011-04-11       Impact factor: 13.506

6.  Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis.

Authors:  Lea A Moukarzel; Ana M Angarita; Christopher VandenBussche; Anne Rositch; Carol B Thompson; Amanda N Fader; Kimberly Levinson
Journal:  J Low Genit Tract Dis       Date:  2017-04       Impact factor: 1.925

7.  Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix with a focal high-grade component: is there a need for reassessment?

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

8.  A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.

Authors:  Eriko Takatori; Tadahiro Shoji; Yasuko Suga; Hanae Niinuma; Yuki Miura; Yoshitaka Kaido; Anna Takada; Masahiro Kagabu; Satoshi Takeuchi; Toru Sugiyama
Journal:  Int J Clin Oncol       Date:  2013-03-14       Impact factor: 3.402

9.  Methylation analysis of SFRP genes family in cervical adenocarcinoma.

Authors:  Ya-Wen Lin; Ming-Tzeung Chung; Hung-Cheng Lai; Ming De Yan; Yu-Leung Shih; Cheng-Chang Chang; Mu-Hsien Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

10.  Declining death rates reflect progress against cancer.

Authors:  Ahmedin Jemal; Elizabeth Ward; Michael Thun
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.